FDAFinal Rule

Medical Devices; Immunology and Microbiology Devices; Classification of the Cellular Analysis System for Multiplexed Antimicrobial Susceptibility Testing

HealthcareTechnology

Summary

The FDA is officially classifying a new laboratory device that can quickly test which antibiotics work best against bacterial infections by analyzing multiple samples at once. This device helps doctors prescribe the right antibiotics faster, which is important because it reduces unnecessary antibiotic use and helps fight the growing problem of antibiotic-resistant bacteria.

Key Points

  • 1The FDA is establishing an official category for a cellular analysis system that tests how bacteria respond to multiple antibiotics simultaneously
  • 2This device speeds up the process of determining which antibiotics will actually work for a patient's infection, rather than guessing and trying different drugs
  • 3The classification helps ensure the device meets safety and effectiveness standards before hospitals and labs can use it
  • 4Faster and more accurate antibiotic testing can reduce the overuse of antibiotics, which helps prevent dangerous drug-resistant bacteria from developing
  • 5This primarily affects hospitals, diagnostic laboratories, and healthcare providers who treat bacterial infections

Impact Assessment

If you are a healthcare provider or clinical laboratory, this means you can now use this newly classified device to quickly identify which antibiotics are effective against specific bacterial infections, enabling faster and more targeted treatment decisions.

Impact Level
Moderate
Geographic Scope

National

Compliance Cost

Moderate

Who is Affected
Healthcare ProvidersManufacturersSmall Businesses

Key Dates

Published

June 13, 2025

Regulatory Connections

Amends CFR Sections
21 CFR Part 86021 CFR Part 866

This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.